Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,730.00-1.92%ETH$2,440.84-1.07%GOLD$4,356.10-1.16%OIL$103.97+1.45%
Smart Investors Daily
BridgeBio Pharma, Inc. logo

NASDAQ · BBIO

BridgeBio Pharma, Inc.

Healthcare · Biotechnology

$76.08

Down-$3.57 (-4.69%)

Updated Sep 10, 2026, 7:48 PM

SID Score

5.1/10

Composite research score

Smart Money

59/100

Neutral

Market cap
14.11B
P/E ratio
-17.71
Dividend yield
0.00%
52-week range
$48.78 – $93.42
Volume
2.31M
Avg. volume
2.32M

Price performance

BBIO price history

1M range · 20 trading sessions · Daily adjusted prices

BBIO closed at $76.08 after 20 trading sessions, down 9.26% for the selected period.

Last close
$76.08
Period change
-9.26%
Period low
$74.76
Period high
$83.95
Daily close
View OHLC price history
BBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$73.63$76.81$73.465$76.082.31M
Sep 8, 2026$73.60$76.34$73.26$74.762.09M
Sep 4, 2026$74.98$75.365$74.11$74.841.54M
Sep 3, 2026$76.43$76.64$75.20$75.411.1M
Sep 2, 2026$76.60$78.2499$75.955$76.501.62M
Sep 1, 2026$76.61$77.451$76.22$76.571.45M
Aug 31, 2026$76.20$77.235$75.02$76.592.06M
Aug 28, 2026$79.99$80.55$76.34$76.601.92M
Aug 27, 2026$79.25$79.725$78.34$78.681.03M
Aug 26, 2026$79.75$80.76$79.33$79.371.71M
Aug 25, 2026$81.89$82.50$80.20$80.401.47M
Aug 24, 2026$80.98$81.68$80.16$81.071.11M
Aug 21, 2026$82.89$83.3667$81.36$81.501.74M
Aug 20, 2026$83.51$84.3646$82.63$82.942.03M
Aug 19, 2026$84.22$85.65$83.25$83.953.29M
Aug 18, 2026$80.54$83.95$80.10$82.982.72M
Aug 17, 2026$79.15$80.42$78.125$79.892.8M
Aug 14, 2026$80.14$80.56$78.60$79.863.09M
Aug 13, 2026$84.77$84.77$80.78$81.211.28M
Aug 12, 2026$83.47$84.99$82.82$83.842.79M

Latest BBIO news

The latest Smart Investors Daily articles mentioning BBIO.

Stock researchCompany · Overview

BBIO research

Overview

Company profile and research snapshot.

Company profile

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$85.00
Implied upside
—
Analysts
—
BBIO recent ratings
DateFirmRatingTarget
Sep 2, 2026HC Wainwright & Co.Buy—
Sep 1, 2026MizuhoOutperform—
Aug 12, 2026Canaccord GenuityBuy—
Aug 12, 2026Truist SecuritiesBuy—
Aug 12, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is asking investors to look beyond disease stabilization in transthyretin amyloid cardiomyopathy, or ATTR-CM. New cardiac magnetic resonance imaging data from the Phase 3 ATTRibute-CM study and its open-label extension suggested that some acoramidis-treated patients experienced improvements in cardiac structure and function. A separate post-hoc analysis found that treatment preserved more […]

Yahoo · Sep 2, 2026

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By